119,136 Boston Scientific Corporation $BSX Shares Sold by Calamos Advisors LLC

Posted by Francis Steltz on Nov 7th, 2026

Boston Scientific logo Calamos Advisors LLC lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 17.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 557,978 shares of the medical equipment provider’s stock after selling 119,136 shares during the period. Calamos Advisors LLC’s holdings in Boston Scientific were worth $24,356,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the second quarter worth about $2,156,233,000. Jupiter Topco LLC bought a new stake in Boston Scientific in the second quarter valued at approximately $803,357,000. Janus Henderson Group PLC boosted its holdings in Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Finally, Amundi increased its position in Boston Scientific by 1.2% during the 2nd quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock valued at $610,158,000 after purchasing an additional 173,208 shares during the period. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Mizuho set a $50.00 price target on shares of Boston Scientific in a research report on Thursday, October 29th. Stifel Nicolaus lowered their target price on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Raymond James Financial restated an “outperform” rating and issued a $57.00 target price (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Argus cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Finally, Wells Fargo & Company decreased their price target on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

View Our Latest Analysis on Boston Scientific

Boston Scientific Stock Down 4.1%

NYSE:BSX traded down $1.82 during trading hours on Friday, reaching $42.82. The company had a trading volume of 14,710,150 shares, compared to its average volume of 18,989,676. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market cap of $62.05 billion, a price-to-earnings ratio of 18.14, a P/E/G ratio of 1.29 and a beta of 0.60. The business’s 50-day simple moving average is $44.32 and its two-hundred day simple moving average is $55.70.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. On average, equities analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.